LaMarche, Nelson M.
Hegde, Samarth
Park, Matthew D.
Maier, Barbara B.
Troncoso, Leanna http://orcid.org/0000-0003-2529-9267
Le Berichel, Jessica
Hamon, Pauline http://orcid.org/0000-0002-6776-1635
Belabed, Meriem
Mattiuz, Raphaël http://orcid.org/0000-0002-3292-1635
Hennequin, Clotilde
Chin, Theodore
Reid, Amanda M.
Reyes-Torres, Iván
Nemeth, Erika
Zhang, Ruiyuan
Olson, Oakley C.
Doroshow, Deborah B.
Rohs, Nicholas C.
Gomez, Jorge E.
Veluswamy, Rajwanth
Hall, Nicole
Venturini, Nicholas http://orcid.org/0000-0002-3769-5956
Ginhoux, Florent http://orcid.org/0000-0002-2857-7755
Liu, Zhaoyuan
Buckup, Mark
Figueiredo, Igor
Roudko, Vladimir
Miyake, Kensuke http://orcid.org/0000-0003-1149-3755
Karasuyama, Hajime http://orcid.org/0000-0003-0689-0836
Gonzalez-Kozlova, Edgar http://orcid.org/0000-0002-6948-0626
Gnjatic, Sacha http://orcid.org/0000-0001-5643-9520
Passegué, Emmanuelle http://orcid.org/0000-0002-3516-297X
Kim-Schulze, Seunghee
Brown, Brian D. http://orcid.org/0000-0002-3670-8778
Hirsch, Fred R.
Kim, Brian S. http://orcid.org/0000-0002-8100-7161
Marron, Thomas U. http://orcid.org/0000-0001-5903-8191
Merad, Miriam http://orcid.org/0000-0002-4481-7827
Article History
Received: 10 March 2023
Accepted: 30 October 2023
First Online: 6 December 2023
Competing interests
: M.M. and T.U.M. have submitted a patent related to the clinical trial described in this study. M.M. serves on the scientific advisory board and holds stock from Compugen Inc., Myeloid Therapeutics Inc., Morphic Therapeutic Inc., Asher Bio Inc., Dren Bio Inc., Oncoresponse Inc., Owkin Inc., Larkspur Inc. and DEM BIO, Inc. M.M. serves on the scientific advisory board of Innate Pharma Inc., OSE Inc. and Genenta Inc. M.M. receives funding for contracted research from Regeneron Inc. and Boerhinger Ingelheim Inc. T.U.M. has served on Advisory and/or Data Safety Monitoring Boards for Rockefeller University, Regeneron Pharmaceuticals, Abbvie, Bristol Myers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, Glenmark, Simcere, Surface, G1 Therapeutics, NGMbio, DBV Technologies, Arcus and Astellas, and has research grants from Regeneron, Bristol-Myers Squibb, Merck and Boehringer Ingelheim. B.S.K. is a consultant for Regeneron and Sanofi. D.B.D. sits on the advisory boards of Astrazeneca, Mirati Therapeutics, Summit Therapeutics, G1 Therapeutics and Sanofi, and is a consultant for Sonata Therapeutics. S.G. reports other research funding from Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Regeneron and Takeda not related to this study.